Stockscreener 앱 받기
5.08
1.93%
-0.10
시간 외 거래:
5.08
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
Coya Therapeutics stock maintained at Buy by H.C. Wainwright - Investing.com
Coya 302: A New Approach to Neurodegeneration - ALS News Today
Coya Enrolls 100 Patients in Phase 2/3 ALS Trial of COYA 302 - Streetwise Reports
Coya Therapeutics Advances COYA 302 ALS Trial With 100th Participant - Streetwise Reports
Coya Therapeutics (COYA) Stock Price, News & Analysis - MarketBeat
Coya Therapeutics Hits Enrollment Milestone with 100 Patients in Phase 2/3 ALSTARS ALS Trial - Kalkine Media
Trial of potential ALS treatment approaches full enrollment - ALS News Today
Form 8K Coya Therapeutics Inc For: 15 September By Investing.com - Investing.com Nigeria
Coya Therapeutics Price Target Maintained With a $16.00/Share by BTIG - Moomoo
Coya Therapeutics Advances COYA 302 ALS Phase 2/3 Trial - TipRanks
Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
Coya Therapeutics, Inc. Common Stock (NASDAQ: COYA) Stock Price, News & Analysis - kalkine.ca
Coya Therapeutics (COYA) Rises Modestly as Shares Hold Above $4.41 SupportMomentum Surge Alerts - dars.gov.et
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation - BioSpace
$32 Million Exosome Therapy Market Assessment 2026: Set to Experience Massive Growth, Reaching $1.4 Billion by 2040 - GlobeNewswire Inc.
COYA: Treg-based combination therapies show promise in ALS and FTD, with key data expected in 2027 - TradingView
Coya Therapeutics Advances Phase 2 ALSTARS ALS Trial Toward 2026 Enrollment Finish - Streetwise Reports
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Is This Biopharmaceutical Co. Developing ALS Drug a Buy? - Streetwise Reports
H.C. Wainwright reiterates Coya Therapeutics stock rating at buy By Investing.com - Investing.com UK
Coya (COYA) Outlook: Records a 0.21% Increase to $4.87 at the Close; Next Test: Traders Can Monitor the $4.63-$5.11 Range at the CloseDouble Bottom - careplusvn.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
COYA|Coya Therapeutics Inc|Price:4.790|Chg%:+0.120 - TradingKey
Coya Therapeutics (COYA) Holds Ground at $4.67 as Consolidation ContinuesOBV Divergence - vinanet.vn
Experimental ALS treatment being tested in Philadelphia: "There's potential here for a home run" - CBS News
Coya Therapeutics (COYA) Edges Up 0.85% to $4.73, Holding Support Amid ConsolidationGEX Level - vinanet.vn
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss Offers a Favorable SurpriseNext Quarter Guidance - vinanet.vn
COYA Pulls Back to $4.69: Coya Therapeutics Approaches Critical Support LevelHigh Dividend Factor - vinanet.vn
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Form 8K Coya Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Coya Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases - Bitget
Coya Therapeutics reports Q2 2026 net loss $6.64M, cash $43.2M; ALSTARS Phase 2 enrollment on track - TradingView
Coya Therapeutics Q2 net loss widens as R&D costs rise - TradingView
Coya Therapeutics Reports Q2 Net Loss of $6.6 Million - Quiver Quantitative
Coya Therapeutics (NASDAQ: COYA) details Q2 2026 results, ALS Fast Track and cash runway - Stock Titan
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics (NASDAQ:COYA): What Could Today’s Update Reveal About Clinical Execution And Funding Priorities? - Kalkine Media
COYA Q1 2026 Earnings: 24.1% EPS Beat Narrows Loss, Shares Rise 1.72%Special Dividend Alert - dars.gov.et
IMDX Stock Price and Chart — NASDAQ:IMDX - tradingview.com
Coya Therapeutics (NASDAQ: COYA) names Mark Pavao to its Audit Committee - Stock Titan
Coya Therapeutics, Inc. Appoints Mark H. Pavao to Its Audit Committee of Board, Effective August 7, 2026 - marketscreener.com
Coya Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Coya Therapeutics (COYA) Rallies 3.71% as Shares Press Toward Key $5 LevelFear Greed Index - careplusvn.com
Treg Therapy Market - Future Market Insights
Coya Therapeutics (COYA) Expected to Release Earnings on Tuesday - MarketBeat
Avoiding Lag: Real-Time Signals in (COYA) Movement - Stock Traders Daily
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Drives 2.7% Stock UptickShare Dilution Risk - dars.gov.et
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 24.1% EPS Surprise, Shares Rise 2.7%Return On Equity - dars.gov.et
COYA Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 5.4%High Estimate Range - dars.gov.et
Coya Therapeutics (COYA) Holds Steady at $4.0 Amid Key Support and Resistance BattleEarnings Sentiment - careplusvn.com
Coya Therapeutics (NASDAQ: COYA) holder discloses 3.3% stake in amended filing - Stock Titan
Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Coya Therapeutics Inc (COYA) Balance Sheet - TradingKey
Coya Therapeutics Inc (COYA) Cash Flow - TradingKey
Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
COYA|Coya Therapeutics Inc|Price:4.250|Chg%:-0.130 - TradingKey
3.06%
2.55%
자본화:
|
볼륨(24시간):